TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04509297

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high protein milk
Description: This intervention consisted of high protein milk consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: high protein milk
Description: This intervention consisted of high protein milk consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This intervention consisted of the consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This intervention consisted of the consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
Study: NCT01241318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (4%)
Description: Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry cord care
Description: Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
Study: NCT04340687

Intervention type: DEVICE
Intervention: Pancreatic duct stenting
Description: A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice
Study: NCT03075930

Intervention type: DEVICE
Intervention: Extended Electrocardiogram
Description: ECG with 3 additional leads and a 5 minute recording

Intervention type: DEVICE
Intervention: Body surface potential map
Description: ECG with 184 leads and a 5 minute recording
Study: NCT00933374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
Study: NCT03542344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Single rising oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single rising oral dose
Study: NCT03707327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game Ready
Description: the participants remained for 20 minutes with intermittent compression therapy + cryotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack
Description: the participants remained for 20 minutes with cryotherapy with ice pack
Study: NCT03789045

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic thresholds and fat oxidation points relationship
Description: Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic thresholds and fat oxidation points relationship
Description: Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic thresholds and fat oxidation points relationship
Description: Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.
Study: NCT02432404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing
Study: NCT02060149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C/S plus minocycline.
Description: Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C/S plus minocycline.
Description: Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: C/S plus minocycline.
Description: Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulization with pH 7.4 solution
Description: Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulization with pH 7.8 solution
Description: Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: No nebulization
Description: No nebulization will be given to the patients.
Study: NCT00329654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy with the Embar® light therapy or sham irradiation
Description: Phototherapy with the Embar® light therapy or sham irradiation is followed.
Study: NCT02848183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Study: NCT04122092

Intervention type: DIAGNOSTIC_TEST
Intervention: The level of plasma cfDNA CINs
Description: The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs
Study: NCT00268996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-480848
Description: SB-480848 is available as enteric-coated, free-base micronized tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-480848
Description: SB-480848 is available as enteric-coated, free-base micronized tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SB-480848 matching placebo
Description: Placebo is available as enteric-coated, free-base micronized tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SB-480848 matching placebo
Description: Placebo is available as enteric-coated, free-base micronized tablet
Study: NCT01862562

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Conventional technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: New minimum invasive technique
Study: NCT00061698

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy Child Only
Description: Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy Child Only
Description: Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT plus Parent Training
Description: Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief. Parents learned skills that helped their child to apply the strategies they learned. Parents learned how to better communicate positive information that helped their child build a positive core belief. Parents learned how to use reinforcement to support healthy behavior.
Study: NCT00331279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cinnamon Extract
Description: A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills in likeness of the cinnamon extract
Study: NCT03627689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active air purifier in respiratory allergies/asthma
Description: Continuous use of air purifier to improve allergies and asthma control

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham air purifier
Description: control arm
Study: NCT04451395

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (UNIMMAP composition)
Description: The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000
Study: NCT02520102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim GZ402664
Description: Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous
Study: NCT02504606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besylsartan
Description: Amlodipin besylate 6.944mg+Losartan K 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amosartan
Description: Amlodipin besylate 7.841mg+Losartan K 100mg
Study: NCT00532064

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT04181502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pneumatic tourniquet
Description: a pneumatic tourniquet around 200 mmHg after venous chase of the lower limb, during 5 minutes then deflated. Repeated twice after general anaesthesia and prior to incision.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No inflation
Description: No inflation of the pneumatic tourniquet placed on the lower limb
Study: NCT00532064

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01917136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-acetate
Description: For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluoro-2-deoxy-2-D-glucose
Description: For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
Study: NCT01914900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin, 5 fluorouracil
Study: NCT02659631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06671008
Description: Dose Escalation Phase - Part 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06671008
Description: Dose Expansion Phase - Part 2
Study: NCT02550366

Intervention type: DRUG
Intervention: MRI Contrast
Description: MRI Contrast
Study: NCT02211521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: 3ml of PRP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: 3ml hyaluronic acid
Study: NCT00871117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals'Kinrix®
Description: One dose as intramuscular injection at visit 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals'Kinrix®
Description: One dose as intramuscular injection at visit 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Merck and Company's MMRII
Description: One dose as subcutaneous injection at visit 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Merck and Company's MMRII
Description: One dose as subcutaneous injection at visit 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Merck and Company's Varivax
Description: One dose as subcutaneous injection at visit 1 or at visit 2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Merck and Company's Varivax
Description: One dose as subcutaneous injection at visit 1 or at visit 2
Study: NCT03293433

Intervention type: OTHER
Intervention: Blood punction
Description: 1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of micro RNA.
Study: NCT01218100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol and lisinopril (free combination)
Description: nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebivolol monotherapy
Description: nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril monotherapy
Description: lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
Study: NCT02887053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT02178813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of minocycline
Description: Administration of minocycline with the following schedule:~* Day prior to procedure: 800mg p.o., 700mg p.o.~* Day of procedure: 600mg i.v., 500mg p.o.~* Day after procedure: 400mg p.o., 400mg p.o.
Study: NCT03403231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
Study: NCT03353636

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: 150mg elemental magnesium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: 150mg elemental magnesium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: 150mg elemental magnesium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: 150mg elemental magnesium
Study: NCT03403231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
Study: NCT03353636

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour
Study: NCT04108403

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Inducing Massage
Description: A pain inducing massage (pain intensity = 50/100) will be applied for 60 seconds, 4 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Inducing Massage
Description: A pain inducing massage (pain intensity = 50/100) will be applied for 60 seconds, 4 times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Free Massage
Description: A pain free massage (pain intensity = 0/100) will be applied for 60 seconds, 4 times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Free Massage
Description: A pain free massage (pain intensity = 0/100) will be applied for 60 seconds, 4 times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Expectation Instructional Set
Description: Participants will be instructed that the massage is effective for some people with neck pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Expectation Instructional Set
Description: Participants will be instructed that the massage is effective for some people with neck pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative Expectation Instructional Set
Description: Participants will be instructed that the massage is ineffective for some people with neck pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative Expectation Instructional Set
Description: Participants will be instructed that the massage is ineffective for some people with neck pain.
Study: NCT02394613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX776
Description: Single intravenous injection